Table 3 Evolution of clinical phenotypes of Behçet’s disease in Japan after correction for the follow-up period
Group A Pre 2000 (n = 293) | Group B 2000–2007 (n = 160) | Group C Post 2008 (n = 91) | P | |
|---|---|---|---|---|
Observation time (years) | 3.52 ± 1.6 | 3.25 ± 1.7 | 3.7 ± 2.2 | NS |
Age at onset | 36.4 ± 11.9 | 35.8 ± 13.0 | 37.6 ± 11.4 | NS |
Gender male, n (%) | 121 (41.3) | 74 (46.3) | 37 (40.7) | 0.81 |
HLA-B51, n (%) | 103 (53.4) | 47 (50.0) | 16 (43.1) | 0.031 a |
Complete type, n (%) | 99 (33.8) | 37 (23.1) | 16 (17.6) | 0.0008 |
Oral ulcer, n (%) | 291 (99.3) | 159 (99.4) | 88 (96.7) | 0.079 |
Genital ulcer, n (%) | 219 (74.7) | 112 (70.0) | 55 (60.4) | 0.0096 |
Eye involvement, n (%) | 184 (62.8) | 85 (53.1) | 53 (58.2) | 0.19 |
Skin involvement, n (%) | 255 (87.0) | 137 (85.6) | 75 (82.4) | 0.28 |
GI, n (%) | 18 (6.1) | 19 (11.9) | 14 (16.5) | 0.0036 |
CNS, n (%) | 20 (6.8) | 14 (8.8) | 3 (3.3) | 0.46 |
Vascular, n (%) | 17 (5.8) | 15 (9.4) | 3 (3.3) | 0.73 |
Complete type fulfilling, n ISG (%) | 99/264 (37.5) | 37/135 (27.4) | 16/74 (21.6) | 0.0037 |
Complete type w/o GI, n (%) | 96/275 (34.9) | 35/141 (24.8) | 15/77 (19.5) | 0.0030 |